Skip to main content
logo
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.37
-0.27 (-3.13%)
At close: Aug 28, 2026, 4:00 PM EDT
8.53
+0.16 (1.91%)
After-hours: Aug 28, 2026, 7:30 PM EDT

Kyverna Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----7.035.66
Revenue Growth
----24.20%-
Cost of Revenue
---49.9228.425.85
Gross Profit
----49.92-21.38-20.2
Selling, General & Admin
43.636.1130.1312.488.016.15
Research & Development
115.33133.72112.47---
Operating Expenses
158.93169.83142.612.488.016.15
Operating Income
-158.93-169.83-142.6-62.41-29.38-26.35
Interest Expense
-1.79-0.49-0.14-0.19-0.07-0
Interest & Investment Income
8.169.0915.362.280.570
Other Non Operating Income (Expenses)
-0.08-0.09-0.09-0.06-0.01-0
Pretax Income
-152.64-161.31-127.48-60.37-28.89-26.35
Net Income
-152.64-161.31-127.48-60.37-28.89-26.35
Net Income to Common
-152.64-161.31-127.48-60.37-28.89-26.35
Net Income Growth
------
Shares Outstanding (Basic)
534438100
Shares Outstanding (Diluted)
534438100
Shares Change
22.58%15.46%5590.81%47.89%71.30%-
EPS (Basic)
-2.88-3.64-3.33-89.61-63.43-99.10
EPS (Diluted)
-2.88-3.64-3.33-89.61-63.43-99.10
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-159.05-153.72-116.46-53.03-36.88-23.44
Free Cash Flow Per Share
-3.00-3.47-3.04-78.72-80.97-88.17
Operating Margin
-----418.28%-465.81%
Profit Margin
-----411.29%-465.88%
Free Cash Flow Margin
-----525.00%-414.50%
EBITDA
-157.36-168.03-140.47-60.7-28.61-25.76
D&A For EBITDA
1.571.82.131.710.780.59
EBIT
-158.93-169.83-142.6-62.41-29.38-26.35
SEC Filings: 10-K · 10-Q